Sydnexis, Inc., ( a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced topline results from the Phase 3 STAR trial of SYD-101, a proprietary 0.01% atropine ...
In a data-driven world, pauses in government economic data do more than inconvenience economists, they create dangerous blind spots for investors and business leaders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback